• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by TFF Pharmaceuticals Inc. (Amendment)

    2/9/23 4:30:00 PM ET
    $TFFP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TFFP alert in real time by email
    SC 13G/A 1 d407072dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    TFF Pharmaceuticals, Inc.

    (Name of Issuer)

    Common Stock, $0.001 par value per share

    (Title of Class of Securities)

    87241J104

    (CUSIP Number)

    December 31, 2022

    (Date of Event Which Requires Filing of This Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed :

     

      ☐

    Rule 13d-1(b)

     

      ☒

    Rule 13d-1(c)

     

      ☐

    Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 87241J104    SCHEDULE 13G    Page 2 of 11 Pages

     

      1    

      NAMES OF REPORTING PERSON

     

      Double Black Diamond Offshore Ltd.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Cayman Islands

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      0

       6  

      SHARED VOTING POWER

     

      1,842,000

       7  

      SOLE DISPOSITIVE POWER

     

      0

       8  

      SHARED DISPOSITIVE POWER

     

      1,842,000

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      1,842,000

    10  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      5.1%

    12  

      TYPE OF REPORTING PERSON

     

      CO

     

    2


    CUSIP No. 87241J104    SCHEDULE 13G    Page 3 of 11 Pages

     

      1    

      NAMES OF REPORTING PERSON

     

      Carlson Capital, L.P.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      0

       6  

      SHARED VOTING POWER

     

      1,842,000

       7  

      SOLE DISPOSITIVE POWER

     

      0

       8  

      SHARED DISPOSITIVE POWER

     

      1,842,000

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      1,842,000

    10  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      5.1%

    12  

      TYPE OF REPORTING PERSON

     

      PN, IA

     

    3


    CUSIP No. 87241J104    SCHEDULE 13G    Page 4 of 11 Pages

     

      1    

      NAMES OF REPORTING PERSON

     

      Asgard Investment Corp. II

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      0

       6  

      SHARED VOTING POWER

     

      1,842,000

       7  

      SOLE DISPOSITIVE POWER

     

      0

       8  

      SHARED DISPOSITIVE POWER

     

      1,842,000

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      1,842,000

    10  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      5.1%

    12  

      TYPE OF REPORTING PERSON

     

      CO

     

    4


    CUSIP No. 87241J104    SCHEDULE 13G    Page 5 of 11 Pages

     

      1    

      NAMES OF REPORTING PERSON

     

      Clint D. Carlson

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      0

       6  

      SHARED VOTING POWER

     

      1,842,000

       7  

      SOLE DISPOSITIVE POWER

     

      0

       8  

      SHARED DISPOSITIVE POWER

     

      1,842,000

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      1,842,000

    10  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      5.1%

    12  

      TYPE OF REPORTING PERSON

     

      IN

     

    5


    Explanatory Note

    This Amendment No. 1 (this the “Amendment”) amends the initial statement on Schedule 13G filed by the Reporting Persons on November 22, 2022 (as amended prior to the date hereof, the “Original Filing”, and as amended by this Amendment No. 1, the “Statement”).

     

    Item 1(a).

    NAME OF ISSUER

    TFF Pharmaceuticals, Inc., a Delaware corporation (the “Issuer”).

     

    Item 1(b).

    ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES

    1751 River Run, Suite 400

    Fort Worth, Texas 76107

     

    Item 2(a).

    NAME OF PERSON FILING

    This statement is filed by:

    (i) Double Black Diamond Offshore Ltd., a Cayman Islands exempted company (the “Fund”), with respect to Common Stock, par value $0.001 per share, of the Issuer (the “Common Stock”) held or beneficially owned directly by the Fund;

    (ii) Carlson Capital, L.P., a Delaware limited partnership (“Carlson Capital”), which serves as the investment manager to the Fund with respect to any shares of Common Stock of the Issuer held by the Fund;

    (iii) Asgard Investment Corp. II, a Delaware corporation (“Asgard II”), which serves as the general partner of Carlson Capital, with respect to the Common Stock directly held by the Fund; and

    (iv) Mr. Clint D. Carlson, a United States citizen (“Mr. Carlson”), who is the sole stockholder of Asgard II and serves as president of Asgard II and Carlson Capital, with respect to the Common Stock directly held by the Fund.

    The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons”.

    The filing of this statement should not be construed as an admission that any of the Reporting Persons is, for the purposes of Section 13 of the Act, the beneficial owner of the Common Stock reported herein.

     

    Item 2(b).

    ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE

    The address of the principal business office of each of the Reporting Persons is 2100 McKinney Avenue, Suite 1900, Dallas, Texas 75201.

     

    6


    Item 2(c).

    CITIZENSHIP

    The Fund is a Cayman Islands exempted company. Carlson Capital is a Delaware limited partnership. Asgard II is a Delaware corporation. Mr. Carlson is a United States citizen.

     

    Item 2(d).

    TITLE OF CLASS OF SECURITIES

    Common Stock, par value $0.001 per share (the “Common Stock”).

     

    Item 2(e).

    CUSIP No.

    87241J104

     

    Item 3.

    IF THIS STATEMENT IS FILED PURSUANT TO §§ 240.13D-1(B), OR 240.13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A:

     

                         (a)    ☐    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
      (b)    ☐    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c)    ☐    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d)    ☐    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e)    X    An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
      (f)    ☐    An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
      (g)    ☐    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
      (h)    ☐    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
      (i)    ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
      (j)    ☐    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J).
      (k)    ☐    Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

    If filing as a non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J), please specify the type of institution: __________

     

    7


    Item 4.

    OWNERSHIP

     

      A.

    The Fund:

     

      (a)

    Amount beneficially owned: 1,842,000 shares of Common Stock (consisting of 1,242,000 shares of Common Stock owned, plus 600,000 shares of Common Stock issuable upon exercise of 1,200,000 warrants)

     

      (b)

    Percent of class: 5.1%

     

      (c)

    (i)    Sole power to vote or direct the vote: 0

     

      (ii)

    Shared power to vote or direct the vote: 1,842,000

     

      (iii)

    Sole power to dispose or direct the disposition: 0

     

      (iv)

    Shared power to dispose or direct the disposition: 1,842,000

     

      B.

    Carlson Capital:

     

      (a)

    Amount beneficially owned: 1,842,000

     

      (b)

    Percent of class: 5.1%

     

      (c)

    (i)    Sole power to vote or direct the vote: 0

     

      (ii)

    Shared power to vote or direct the vote: 1,842,000

     

      (iii)

    Sole power to dispose or direct the disposition: 0

     

      (iv)

    Shared power to dispose or direct the disposition: 1,842,000

     

    8


      C.

    Asgard II:

     

      (a)

    Amount beneficially owned: 1,842,000

     

      (b)

    Percent of class: 5.1%

     

      (c)

    (i)    Sole power to vote or direct the vote: 0

     

      (ii)

    Shared power to vote or direct the vote: 1,842,000

     

      (iii)

    Sole power to dispose or direct the disposition: 0

     

      (iv)

    Shared power to dispose or direct the disposition: 1,842,000

     

      D.

    Mr. Carlson:

     

      (a)

    Amount beneficially owned: 1,842,000

     

      (b)

    Percent of class: 5.1%

     

      (c)

    (i)    Sole power to vote or direct the vote: 0

     

      (ii)

    Shared power to vote or direct the vote: 1,842,000

     

      (iii)

    Sole power to dispose or direct the disposition: 0

     

      (iv)

    Shared power to dispose or direct the disposition: 1,842,000

    The percentages reported in this Schedule 13G are based on 36,193,085 shares of Common Stock outstanding on December 20, 2022, as reported in the Issuer’s Proxy Statement on Form DEF14A filed with the Securities and Exchange Commission on December 27, 2022.

     

    Item 5.

    OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.

     

    Item 6.

    OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

    Not applicable.

     

    Item 7.

    IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON

    Not applicable.

     

    Item 8.

    IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP

    Not applicable.

     

    Item 9.

    NOTICE OF DISSOLUTION OF GROUP

    Not applicable.

     

    Item 10.

    CERTIFICATION

    Each of the Reporting Persons hereby makes the following certification:

    By signing below, each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    9


    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATED: February 9, 2023

     

    DOUBLE BLACK DIAMOND OFFSHORE LTD.
    By:   Carlson Capital, L.P., its investment manager
    By:   Asgard Investment Corp. II, its general partner
    By:   /s/ Clint D. Carlson
    Name:   Clint D. Carlson
    Title:   President
    CARLSON CAPITAL, L.P.
    By:   Asgard Investment Corp. II, its general partner
    By:   /s/ Clint D. Carlson
    Name:   Clint D. Carlson
    Title:   President
    ASGARD INVESTMENT CORP. II
    By:   /s/ Clint D. Carlson
    Name:   Clint D. Carlson
    Title:   President
    CLINT D. CARLSON
    /s/ Clint D. Carlson

     

    10

    Get the next $TFFP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TFFP

    DatePrice TargetRatingAnalyst
    5/19/2022$22.00Buy
    H.C. Wainwright
    More analyst ratings

    $TFFP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright resumed coverage on TFF Pharmaceuticals with a new price target

      H.C. Wainwright resumed coverage of TFF Pharmaceuticals with a rating of Buy and set a new price target of $22.00

      5/19/22 9:05:50 AM ET
      $TFFP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright reiterated coverage on TFF Pharmaceuticals with a new price target

      HC Wainwright reiterated coverage of TFF Pharmaceuticals with a rating of Buy and set a new price target of $37.00 from $31.00 previously

      3/11/21 8:08:25 AM ET
      $TFFP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on TFF Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of TFF Pharmaceuticals with a rating of Buy and set a new price target of $37.00 from $31.00 previously

      3/5/21 6:29:56 AM ET
      $TFFP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TFFP
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $TFFP
    Financials

    Live finance-specific insights

    See more
    • TFF Pharmaceuticals Announces Delisting from Nasdaq and Potential SEC Deregistration

      FOXBOROUGH, Mass., Feb. 6, 2025 /PRNewswire/ -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) today announced that the Company has provided notification to The Nasdaq Stock Market, LLC ("Nasdaq") of its intent to voluntarily delist the Company's common stock, par value $0.001 per share (the "Common Stock"), from the Nasdaq Capital Market. The Company expects to file a Form 25 (Notification of Removal from Listing) with the Securities and Exchange Commission (the "SEC") and Nasdaq relating to the delisting of its Common Stock on or about February 16, 2025. The removal of the Common Stock from Nasdaq will be effective 10 days after the filing of the Form 25. The Company has made no arrangements for

      2/6/25 4:05:00 PM ET
      $TFFP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TFF Pharmaceuticals Announces It Will Wind Down Operations

      FORT WORTH, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) today announced that the Company has terminated its employees and will wind down its operations. This decision was made at a special meeting of the board of directors. The board of directors appointed Craig R. Jalbert, age 63, as the Company's CEO, President, Chief Financial Officer, Treasurer and Secretary, and sole member of the board. Mr. Jalbert has served as a principal of the Foxborough, Massachusetts accounting firm of Verdolino & Lowey, P.C. since 1987. For over 30 years he has focused his practice in distressed businesses and has served, and continues to serve, in the capacities of office

      11/14/24 4:15:00 PM ET
      $TFFP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TFF Pharmaceuticals' Technology Generates Superior Inhalational Dry Powder Formulations for Pulmonary Drug Delivery

      FORT WORTH, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc (NASDAQ:TFFP) (the "Company" or "TFF Pharmaceuticals"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, announces positive preclinical data published in the Journal of Drug Delivery Science and Technology further validating the Company's TFF technology as superior approach to formulate dry powders for pulmonary drug delivery. The study demonstrates the superiority of TFF inhalational dry powders over jet-milling and spray-drying technologies in a rat model, with enhanced uniform drug

      9/26/24 7:00:00 AM ET
      $TFFP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programs

      Eight of Eight Patients Successfully Transitioned from Oral Tacrolimus to TFF TAC with No Sign of Acute Rejection at Reduced Systemic Exposures Data from TFF VORI Phase 2 and EAP Program Continue to Demonstrate Antifungal Activity and a Favorable Safety and Tolerability Profile TFF TAC Program Prioritized Based on Positive Phase 2 Data, the Potential to Address a Significant Unmet Need in Lung Transplant Medicine and Substantial Market Opportunity Company to Hold Conference Call and Webcast Today at 4:30 pm ET FORT WORTH, Texas , March 27, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) ("the Company"), a clinical-stage biopharmaceutical company focused on developing

      3/27/24 4:01:00 PM ET
      $TFFP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TFF Pharmaceuticals Announces Update on Clinical Programs

      Company to Prioritize Clinical Development of Tacrolimus Inhalation Powder (TFF TAC) based on Positive Phase 2 Data, the Potential to Address a Significant Unmet Need in Lung Transplant Medicine and Substantial Market Opportunity Company to Evaluate Strategic Options for TFF VORI, including Partnerships, Collaborations, and Grants following Positive Data from Phase 2 Study and the Expanded Access Program (EAP) Company to Discuss Clinical Updates on TFF TAC and TFF VORI on Wednesday, March 27, 2024 at 4:30 pm ET FORT WORTH, Texas, March 20, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) ("the Company"), a clinical-stage biopharmaceutical company focused on developing an

      3/20/24 9:03:36 AM ET
      $TFFP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TFF Pharmaceuticals Announces Positive Initial Data from Ongoing Phase 2 Trials of TFF VORI and TFF TAC

      Treatment with TFF VORI resulted in positive treatment outcomes based on clinical, mycologic and radiologic responses while maintaining a favorable safety/tolerability profile, with no all-cause mortality, no invasive pulmonary aspergillosis (IPA)-related mortality, and no TFF VORI discontinuations due to an adverse event (AE) Successful transition of all four patients from oral tacrolimus to TFF TAC, leading to significant lowering of tacrolimus blood levels with no clinical evidence of acute rejection; all patients who completed Part A (study treatment period) of the trial chose to remain on TFF TAC and advance to Part B (extension study) TFF TAC was well tolerated, with no mortality a

      12/19/23 6:00:00 AM ET
      $TFFP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TFFP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by TFF Pharmaceuticals Inc.

      SC 13G/A - TFF Pharmaceuticals, Inc. (0001733413) (Subject)

      11/19/24 4:05:58 PM ET
      $TFFP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by TFF Pharmaceuticals Inc.

      SC 13G - TFF Pharmaceuticals, Inc. (0001733413) (Subject)

      11/14/24 3:37:45 PM ET
      $TFFP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by TFF Pharmaceuticals Inc.

      SC 13G - TFF Pharmaceuticals, Inc. (0001733413) (Subject)

      5/8/24 5:13:05 PM ET
      $TFFP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TFFP
    Leadership Updates

    Live Leadership Updates

    See more
    • TFF Pharmaceuticals Announces It Will Wind Down Operations

      FORT WORTH, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) today announced that the Company has terminated its employees and will wind down its operations. This decision was made at a special meeting of the board of directors. The board of directors appointed Craig R. Jalbert, age 63, as the Company's CEO, President, Chief Financial Officer, Treasurer and Secretary, and sole member of the board. Mr. Jalbert has served as a principal of the Foxborough, Massachusetts accounting firm of Verdolino & Lowey, P.C. since 1987. For over 30 years he has focused his practice in distressed businesses and has served, and continues to serve, in the capacities of office

      11/14/24 4:15:00 PM ET
      $TFFP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TFF Pharmaceuticals Appoints Thomas B. King to Board of Directors

      FORT WORTH, Texas, Dec. 13, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the appointment of Thomas B. King to its Board of Directors. "I am pleased to welcome Thomas King to our Board of Directors," said Harlan Weisman, M.D., Vice Chairman and Chief Executive Officer of TFF Pharmaceuticals. "Tom is an exceptionally accomplished executive who has held leadership positions at life sciences companies over the last three decades. In addition, his extensive board experience will p

      12/13/23 8:00:00 AM ET
      $ACHV
      $TFFP
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • TFF Pharmaceuticals Appoints Michael Patane, Ph.D., to Board of Directors

      FORT WORTH, Texas, Nov. 30, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the appointment of Michael Patane, Ph.D., to its Board of Directors. "I am pleased to welcome Dr. Patane to our Board of Directors," said Harlan Weisman, M.D., Vice Chairman and Chief Executive Officer of TFF Pharmaceuticals. "Mike's career spans over two decades of leadership experience in drug discovery and development, and he has demonstrated an extraordinary ability to turn scientific success into corp

      11/30/23 8:00:00 AM ET
      $TFFP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TFFP
    SEC Filings

    See more
    • SEC Form DEF 14A filed by TFF Pharmaceuticals Inc.

      DEF 14A - TFF Pharmaceuticals, Inc. (0001733413) (Filer)

      12/23/24 6:50:03 AM ET
      $TFFP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by TFF Pharmaceuticals Inc.

      PRE 14A - TFF Pharmaceuticals, Inc. (0001733413) (Filer)

      12/11/24 4:05:37 PM ET
      $TFFP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TFF Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - TFF Pharmaceuticals, Inc. (0001733413) (Filer)

      12/10/24 4:05:34 PM ET
      $TFFP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TFFP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Weisman Harlan F was granted 27,480 shares, increasing direct ownership by 3% to 842,095 units (SEC Form 4)

      4 - TFF Pharmaceuticals, Inc. (0001733413) (Issuer)

      7/8/24 5:46:27 PM ET
      $TFFP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Lee Catherine Chai-Zon was granted 1,583 shares (SEC Form 4)

      4 - TFF Pharmaceuticals, Inc. (0001733413) (Issuer)

      7/8/24 5:44:38 PM ET
      $TFFP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Mills Robert S was granted 3,165 shares, increasing direct ownership by 6% to 59,145 units (SEC Form 4)

      4 - TFF Pharmaceuticals, Inc. (0001733413) (Issuer)

      7/8/24 5:44:15 PM ET
      $TFFP
      Biotechnology: Pharmaceutical Preparations
      Health Care